ABOS
Price
$0.97
Change
-$0.02 (-2.02%)
Updated
Apr 4, 04:59 PM (EDT)
Capitalization
59.76M
46 days until earnings call
APRE
Price
$1.70
Change
-$0.10 (-5.56%)
Updated
Apr 4, 04:54 PM (EDT)
Capitalization
9.78M
Ad is loading...

ABOS vs APRE

Header iconABOS vs APRE Comparison
Open Charts ABOS vs APREBanner chart's image
Acumen Pharmaceuticals
Price$0.97
Change-$0.02 (-2.02%)
Volume$8.5K
Capitalization59.76M
Aprea Therapeutics
Price$1.70
Change-$0.10 (-5.56%)
Volume$100
Capitalization9.78M
ABOS vs APRE Comparison Chart
Loading...
ABOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
APRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABOS vs. APRE commentary
Apr 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABOS is a Hold and APRE is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 05, 2025
Stock price -- (ABOS: $0.99 vs. APRE: $1.80)
Brand notoriety: ABOS and APRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABOS: 143% vs. APRE: 86%
Market capitalization -- ABOS: $59.76M vs. APRE: $9.78M
ABOS [@Biotechnology] is valued at $59.76M. APRE’s [@Biotechnology] market capitalization is $9.78M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABOS’s FA Score shows that 0 FA rating(s) are green whileAPRE’s FA Score has 2 green FA rating(s).

  • ABOS’s FA Score: 0 green, 5 red.
  • APRE’s FA Score: 2 green, 3 red.
According to our system of comparison, APRE is a better buy in the long-term than ABOS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABOS’s TA Score shows that 4 TA indicator(s) are bullish while APRE’s TA Score has 4 bullish TA indicator(s).

  • ABOS’s TA Score: 4 bullish, 4 bearish.
  • APRE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both ABOS and APRE are a good buy in the short-term.

Price Growth

ABOS (@Biotechnology) experienced а -19.67% price change this week, while APRE (@Biotechnology) price change was -18.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.31%. For the same industry, the average monthly price growth was -17.16%, and the average quarterly price growth was -18.95%.

Reported Earning Dates

ABOS is expected to report earnings on May 20, 2025.

APRE is expected to report earnings on May 17, 2023.

Industries' Descriptions

@Biotechnology (-11.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABOS($59.8M) has a higher market cap than APRE($9.78M). ABOS YTD gains are higher at: -42.558 vs. APRE (-45.289). APRE has higher annual earnings (EBITDA): -14.75M vs. ABOS (-77.89M). ABOS has more cash in the bank: 200M vs. APRE (26.2M). APRE has less debt than ABOS: APRE (0) vs ABOS (28.5M). ABOS (0) and APRE (0) have equivalent revenues.
ABOSAPREABOS / APRE
Capitalization59.8M9.78M611%
EBITDA-77.89M-14.75M528%
Gain YTD-42.558-45.28994%
P/E RatioN/AN/A-
Revenue00-
Total Cash200M26.2M763%
Total Debt28.5M0-
TECHNICAL ANALYSIS
Technical Analysis
ABOSAPRE
RSI
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 12 days ago
77%
Bullish Trend about 1 month ago
78%
Declines
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Ad is loading...
ABOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
APRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LVAQX17.93N/A
N/A
LSV Small Cap Value Investor
SEMTX17.22N/A
N/A
Hartford Schroders Emerging Mkts Eq SDR
VESGX43.56N/A
N/A
Vanguard Global ESG Select Stk Admiral
DHIYX17.84N/A
N/A
Diamond Hill International Y
BINAX9.46N/A
N/A
BlackRock Infrastructure Sust Opps Inv A

ABOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABOS has been loosely correlated with FHTX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ABOS jumps, then FHTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABOS
1D Price
Change %
ABOS100%
-8.52%
FHTX - ABOS
53%
Loosely correlated
-7.89%
ATOS - ABOS
50%
Loosely correlated
-6.56%
ALEC - ABOS
49%
Loosely correlated
-7.63%
BEAM - ABOS
48%
Loosely correlated
-10.93%
ATXS - ABOS
47%
Loosely correlated
-6.70%
More

APRE and

Correlation & Price change

A.I.dvisor tells us that APRE and ATOS have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that APRE and ATOS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APRE
1D Price
Change %
APRE100%
-3.74%
ATOS - APRE
32%
Poorly correlated
-6.56%
KPRX - APRE
31%
Poorly correlated
+0.81%
ABOS - APRE
30%
Poorly correlated
-8.52%
ASMB - APRE
28%
Poorly correlated
-1.69%
CRVS - APRE
28%
Poorly correlated
-6.85%
More